R. Brueckner

QRS areas improve the electrocardiographic interpretation of right ventricular hypertrophy.

R. Brueckner, B. Guller, 1987, Computers and biomedical research, an international journal.

Simultaneous Modeling of the Pharmacokinetics and Methemoglobin Pharmacodynamics of an 8-Aminoquinoline Candidate Antimalarial (WR 238605)

L. Fleckenstein, R. Brueckner, 1991, Pharmaceutical Research.

Antibiotic Treatment of Experimental Pneumonic Plague in Mice

J. Ezzell, S. Welkos, A. Friedlander, 1998, Antimicrobial Agents and Chemotherapy.

The Effect of Intraoperative Blood Loss on Serum Cefazolin Level in Patients Undergoing Instrumented Spinal Fusion: A Prospective, Controlled Study

D. Polly, L. Asplund, R. Brueckner, 1996, Spine.

A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.

D. Braitman, G. Shanks, J. Horton, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Population Pharmacokinetics and Pharmacodynamics of Pyridostigmine Bromide for Prophylaxis against Nerve Agents in Humans

K. Lasseter, A. Kaminskis, M. Marino, 1998, Journal of clinical pharmacology.

Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand.

D. Braitman, D. Kyle, W. Milhous, 1999, The Journal of infectious diseases.

First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial.

K. Lasseter, E. Lin, B. Schuster, 1998, The American journal of tropical medicine and hygiene.

Prophylaxis of Plasmodium falciparumInfection in a Human Challenge Model with WR 238605, a New 8-Aminoquinoline Antimalarial

D. Wesche, B. Schuster, R. Brueckner, 1998, Antimicrobial Agents and Chemotherapy.

Arteether toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and multiple doses

Qigui Li, J. Peggins, T. Brewer, 1999, European Journal of Drug Metabolism and Pharmacokinetics.